Immunotherapy for non-small cell lung cancer

被引：11
作者：
Vafadar, Sam [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL 33612 USA
来源：
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2019年 / 32卷 / 09期
关键词：
non-small cell lung cancer; immunotherapy; nivolumab; pembrolizumab; atezolizumab; durvalumab; ADVERSE EVENTS; OPEN-LABEL; PEMBROLIZUMAB; NIVOLUMAB; DOCETAXEL;
D O I：
10.1097/01.JAA.0000569792.99069.e6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immunotherapy is a new genre of treatment for patients with advanced cancer. Initially approved for use in metastatic melanoma, immunotherapy has found a significant place in treating non-small cell lung cancer (NSCLC). Clinical trials using several combinations of immunotherapy are underway to help to determine the best treatment for specific patient groups. This article reviews approved uses of immunotherapy for NSCLC, immune-related toxicities, and explores the future direction of this treatment.
引用
收藏
页码：37 / 42
页数：6
相关论文
共 37 条
[1]   Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].
Alley, Evan W. ;
Lopez, Juanita ;
Santoro, Armando ;
Morosky, Anne ;
Saraf, Sanatan ;
Piperdi, Bilal ;
van Brummelen, Emilie .
LANCET ONCOLOGY, 2017, 18 (05) :623-630
[2]   Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer [J].
Anagnostou, Valsamo K. ;
Brahmer, Julie R. .
CLINICAL CANCER RESEARCH, 2015, 21 (05) :976-984
[3]  
[Anonymous], 2019, Key statistics for lung cancer
[4]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[5]  
AstraZeneca, SAFETY
[6]  
AstraZeneca Pharmaceuticals LP, IMF PRESCR INF
[7]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[8]  
Bristol-Myers Squibb, OPD PRESCR INF
[9]   Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer [J].
Daly, Megan E. ;
Monjazeb, Arta M. ;
Kelly, Karen .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) :1685-1693
[10]   Lung Cancer: Epidemiology, Etiology, and Prevention [J].
Dela Cruz, Charles S. ;
Tanoue, Lynn T. ;
Matthay, Richard A. .
CLINICS IN CHEST MEDICINE, 2011, 32 (04) :605-+
1234